Dennis Ding (Jefferies) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Dennis Ding's stock ratings?

About 48% of Dennis's ratings were profitable over a one-year hold, with an average return of -2.8% per rating, measured by 13Foresight from historical prices.

Q: How is Dennis ranked?

Dennis Ding is ranked #2377 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Dennis Ding

JEF

Dennis Ding

Jefferies

Wall Street Analyst

★☆☆☆☆

#2377

on 13Foresight · ranked by our own returns

48%

Success Rate

-2.8%

Average Return

12 of 25 calls profitable · -16.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 48% of Dennis Ding's ratings turned a profit when each position was held for 1 year — averaging -2.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

21 Buy 7 Hold 0 Sell

Dennis's Stock Coverage 23 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
TEVA Teva Pharmaceutical	Jun 18, 2026	BUY	Buy -6.8% avg upside 39 analysts	$40.00 27.12% Upside	·
RYTM Rhythm Pharmaceuticals	Jun 15, 2026	BUY	Strong Buy +25.2% avg upside 19 analysts	$125.00 29.11% Upside	+6.8%
SGP SpyGlass Pharma	May 19, 2026	BUY	Strong Buy +141.9% avg upside 5 analysts	$62.00 231.50% Upside	-11.8%
ESPR Esperion	May 04, 2026	HOLD	Buy +701.2% avg upside 22 analysts	$3.28 4.21% Upside	+1.0%
AMPH Amphastar Pharmaceuticals	Apr 21, 2026	HOLD	Hold +41.2% avg upside 11 analysts	$22.00 17.00% Upside	+2.0%
OLMA Olema Pharmaceuticals	Mar 19, 2026	BUY	Strong Buy +303.7% avg upside 16 analysts	$40.00 320.66% Upside	-38.6%
ROIV Roivant Sciences	Feb 09, 2026	BUY	Strong Buy +2.5% avg upside 17 analysts	$30.00 4.62% Downside	+12.8%
ARDX Ardelyx	Jan 27, 2026	BUY	Strong Buy +124.7% avg upside 21 analysts	$15.00 147.86% Upside	-29.8%
ABUS Arbutus Biopharma	Dec 11, 2025	BUY	Strong Buy +94.1% avg upside 15 analysts	$7.00 53.81% Upside	-6.0%
MLYS Mineralys Therapeutics, Inc.	Sep 03, 2025	HOLD	Strong Buy +82.2% avg upside 12 analysts	$26.00 5.54% Upside	-14.1%
INDV Indivior	Jul 21, 2025	BUY	Strong Buy +2.1% avg upside 9 analysts	$20.00 47.68% Downside	+143.1%
NAMS NewAmsterdam Pharma Company	Jun 11, 2025	BUY	Strong Buy +56.4% avg upside 18 analysts	$45.00 50.86% Upside	+47.6%
LYRA Lyra Therapeutics	Jun 02, 2025	HOLD	Hold +3282.4% avg upside 7 analysts	$30.00 4311.80% Upside	-96.3%
IMVT Immunovant	May 29, 2025	HOLD	Strong Buy +9.0% avg upside 24 analysts	$18.00 49.09% Downside	+123.6%
CRNX Crinetics Pharmaceuticals	Jan 21, 2025	BUY	Strong Buy +121.2% avg upside 20 analysts	$55.00 53.36% Upside	+43.0%
IKT Inhibikase Therapeutics	Nov 07, 2024	BUY	Strong Buy +231.2% avg upside 8 analysts	$8.00 337.19% Upside	-46.0%
ASMB Assembly Biosciences	Sep 19, 2024	BUY	Strong Buy +38.6% avg upside 10 analysts	$35.00 43.28% Upside	+32.2%
RXRX Recursion Pharmaceuticals	Sep 03, 2024	HOLD	Buy +147.3% avg upside 12 analysts	$6.00 85.83% Upside	-23.7%
FLOW Global X U.S. Cash Flow Kings 100 ETF	Jul 30, 2024	BUY	Sell +20.0% avg upside 11 analysts	$45.00 20.02% Upside	+3.8%
VERU Veru	Jul 17, 2024	HOLD	Strong Buy +567.5% avg upside 10 analysts	$1.00 66.09% Downside	-39.6%
JBIO Jade Biosciences	Jun 17, 2024	HOLD	Strong Buy +232.8% avg upside 16 analysts	$70.00 316.14% Upside	-85.3%
TVRD Tvardi Therapeutics	Jul 13, 2023	BUY	Buy +588.1% avg upside 23 analysts	$18.00 584.40% Upside	-87.7%
CORT Corcept Therapeutics	Feb 14, 2023	HOLD	Buy -45.6% avg upside 15 analysts	$22.00 72.56% Downside	+4.8%

🔒 18 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Dennis Ding — Frequently Asked Questions

How accurate are Dennis Ding's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Dennis's ratings were profitable over a one-year hold, with an average return of -2.8% per rating, or -16.3% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Dennis ranked on 13Foresight?

Dennis Ding is currently ranked #2377 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Dennis cover?

Dennis most recently has ratings on TEVA, RYTM, SGP, ESPR, AMPH, OLMA, ROIV, ARDX, ABUS, MLYS, INDV, NAMS and 11 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!